Skip to navigation Site map About Us Careers Contact DISCOVaerie™ Live! SEARCH PRODUCTS R&D INVESTORS A VISIONaerie® approach We discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Learn More Inspiration. Imagination. Innovation. We have a passion for finding new ways to protect vision. With unique scientific and technical expertise, deep clinical insight and a singular focus on addressing the needs of patients and eye care providers, we see the possibilities ahead. Join us in creating the future of eye care! Learn More OUR PRODUCTS We currently market two innovative prescription eye drops for lowering intraocular pressure (IOP) in glaucoma. Learn More OUR RESEARCH We are making significant progress in developing new treatments for dry eye and retinal diseases. Learn More STOCK QUOTE NASDAQ: AERI $10.15USD Nov 24, 4:00 PM ET LATEST NEWS November 4, 2021 Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update October 12, 2021 Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan September 21, 2021 Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO SOCIAL MEDIA 17h Aerie would like to take a moment to express our gratitude for the #VISIONaerie ophthalmology leaders who never settle for the status quo for patients suffering from #eyedisease. We're inspired by your drive to always be innovating & look forward to continuing our support. AeriePharma @AeriePharma Twitter Logo Aerie would like to take a moment to express our gratitude for the #VISIONaerie ophthalmology leaders who never settle for the status quo for patients suffering from #eyedisease. We're inspired by your drive to always be innovating & look forward to continuing our support. Reply Retweet Like 24 Nov 2021 9d When it comes to #glaucoma, it's important for families to talk. Richard Quinones, MD, shares this pearl for #success with patient care in #WisdomYouCanSee. With #AAO2021 coming to an end, you can see all these insights at www.discovaerielive.com. #ophthalmology #VISIONaerie #medicalaffairs LOAD MORE DISCOVaerie™ Live! Visit our virtual destination for the eye care community to get informed and connected. MORE CAREERS AT AERIE We are looking for VISIONaerieS® who share our passion for innovation to protect sight. MORE OUR ESG COMMITMENT Aerie is dedicated to environmental stewardship, social responsibility, and good corporate governance. MORE PRODUCTS Overview Rhopressa® Rocklatan® DISCOVaerie™ Live! R&D Pipeline Glaucoma Ocular Surface Disease - AR-15512 Retinal Disease - AR-1105 Implant - AR-13503 SR Implant - AR-14034 SR Implant Clinical Trials Research Bibliography Investigator Initiated Research Medical Affairs INVESTORS FAQs News & Presentations Stock Information Reports & Filings Corporate Governance Our Leadership Our Board of Directors Contact Us ABOUT US Our Scientific Heritage Aerie At-a-Glance Our Leadership Our Board of Directors Our ESG Commitment CAREERS CONTACT General Inquiries Corporate Headquarters 4301 Emperor Blvd Suite 400 Durham, NC 27703 Tel. +1 919-237-5300 AERIE PHARMACEUTICALS, INC. ©2021 All Rights Reserved. This site intended for U.S. audiences only. Terms of Use Privacy Policy California Residents